Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 04, 2015 10:18 PM ET


Company Overview of Kythera Biopharmaceuticals, Inc.

Company Overview

KYTHERA Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription products for the aesthetic medicine market in the United States and internationally. Its product candidate ATX-101, is an injectable drug in late-stage clinical development for the the reduction of submental fat. The company also maintains research interest in hair and fat biology, pigmentation modulation, and facial contouring. It has a collaboration arrangement with Bayer Consumer Care AG and a related collaboration agreement with Bayer Consumer Care AG’s affiliate, Intendis GmbH to develop and commercialize ATX-101 outside the United St...

30930 Russell Ranch Road

Third Floor

Westlake Village, CA 91362

United States

Founded in 2004

212 Employees



Key Executives for Kythera Biopharmaceuticals, Inc.

Chief Financial Officer
Age: 62
Total Annual Compensation: $336.0K
Chief Medical Officer
Age: 50
Total Annual Compensation: $446.6K
Compensation as of Fiscal Year 2014.

Kythera Biopharmaceuticals, Inc. Key Developments

KYTHERA Biopharmaceuticals, Inc. Announces Board Changes

On October 1, 2015, in connection with the previously announced Amended and Restated Agreement and Plan of Merger, dated as of August 4, 2015, by and among KYTHERA Biopharmaceuticals, Inc., Allergan plc and Keto Merger Sub, Inc. In accordance with the terms of the Merger Agreement, each of Keith R. Leonard, Jr., Camille Samuels, Dennis Fenton, F. Michael Ball, Nathaniel David, Fran ois Kress, Hollings C. Renton, III and Joseph L. Turner resigned from his or her respective position as a member of KYTHERA's board of directors effective as of immediately prior to, and conditioned upon, the closing of the Merger. Upon the effectiveness of such resignations, the directors of Merger Sub as of immediately prior to the Effective Time (A. Robert D. Bailey and Maria Teresa Hilado) became the directors of the Surviving Corporation.

Kythera Biopharmaceuticals, Inc.(NasdaqGS:KYTH) dropped from NASDAQ Biotechnology Index

Kythera Biopharmaceuticals, Inc. will be removed from NASDAQ Biotech Index.

KYTHERA Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss

KYTHERA Biopharmaceuticals, Inc. announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for KYTH-105 (setipiprant) for treatment of androgenetic alopecia (AGA), or male pattern hair loss. KYTHERA plans to conduct a human proof-of-concept study to evaluate the efficacy and safety of setipiprant in male subjects with AGA, an inherited genetic disorder that is characterized by a recession of the hairline, hair thinning and progression to partial or complete baldness in men. Setipiprant is a selective oral antagonist of the prostaglandin D2 (PGD2) receptor – a possible key variable in hair loss and is a well-characterized molecule supported by a safety database. Setipiprant has been previously evaluated by Actelion Pharmaceuticals Ltd. in nine clinical studies as a potential allergic inflammation treatment, including a Phase III trial in seasonal allergic rhinitis patients and a Phase II proof-of-concept study in asthma patients, resulting in a safety database of more than 1,000 patients with no safety issues identified. KYTHERA is pursuing the clinical development of KYTH-105 under two separate license agreements with Actelion Pharmaceuticals Ltd. and the University of Pennsylvania, which provide KYTHERA with exclusive worldwide rights to KYTH-105, as well as certain patent rights covering the use of PGD2 receptor antagonists for the treatment of hair loss.

Similar Private Companies By Industry

Company Name Region
Xenerex Biosciences, Inc. United States
Lundbeck Research USA, Inc. United States
eBioscience, Inc. United States
Vedantra Pharmaceuticals, Inc. United States
Elan Pharmaceutical Investments Ltd. United States

Recent Private Companies Transactions

June 17, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Kythera Biopharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at